First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial

Yelena Y. Janjigian(Cornell University), Steven B. Maron(Memorial Sloan Kettering Cancer Center), Walid K. Chatila(Memorial Sloan Kettering Cancer Center), Brittanie M Millang(Memorial Sloan Kettering Cancer Center), Shweta S. Chavan(Memorial Sloan Kettering Cancer Center), Carly Alterman(Memorial Sloan Kettering Cancer Center), Joanne F. Chou(Memorial Sloan Kettering Cancer Center), Michal Segal(Memorial Sloan Kettering Cancer Center), Marc Simmons(Memorial Sloan Kettering Cancer Center), Parisa Momtaz(Memorial Sloan Kettering Cancer Center), Marina Shcherba(Memorial Sloan Kettering Cancer Center), Geoffrey Y. Ku(Memorial Sloan Kettering Cancer Center), Alice Zervoudakis(Memorial Sloan Kettering Cancer Center), Elizabeth Won(Memorial Sloan Kettering Cancer Center), David P. Kelsen(Cornell University), David H. Ilson(Memorial Sloan Kettering Cancer Center), Rebecca J. Nagy(Guardant (United States)), Richard B. Lanman(Guardant (United States)), Ryan Ptashkin(Memorial Sloan Kettering Cancer Center), Mark T.A. Donoghue(Molecular Oncology (United States)), Marinela Capanu(Memorial Sloan Kettering Cancer Center), Barry S. Taylor(Memorial Sloan Kettering Cancer Center), David B. Solit(Cornell University), Nikolaus Schultz(Molecular Oncology (United States)), Jaclyn F. Hechtman(Memorial Sloan Kettering Cancer Center)

The Lancet Oncology

May 18, 2020

Cited by 354Open Access